CRL · 10-Q · 2026Q2 · Full report
Acquisition / Partnership / Divestiture
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · 2026-08-05 · Importance 71 · Surprise 60 · Matches filing data
Charles River acquired an additional 79% interest in PathoQuest SAS on April 17, 2026, for $67.6 million, funded with cash and Credit Facility proceeds. It also acquired a Cambodian non-human-primate supplier on January 14, 2026, for a preliminary purchase price of $507.3 million, including $335.0 million paid at closing and $172.3 million of deferred consideration. The company sold European Discovery Services businesses to IQVIA for $125.2 million in cash and sold its CDMO and Cell Solutions businesses to GI Partners, recognizing a $181.7 million first-half loss and retaining potential funding obligations of up to $45.0 million.
Key facts
- Charles River may be required to fund up to $45.0 million of future EBITDA losses and capital expenditures of the divested CDMO and Cell Solutions businesses over a four year period. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| liability | negative | contingent | -0.0% | Charles River may be required to fund up to $45.0 million of future EBITDA losses and capital expenditures of the divested CDMO and Cell… |